Open AccessEvaluation of a New Heparin Agent in Percutaneous Coronary Intervention
Author(s) -
Sunil V. Rao,
Chiara Melloni,
Shelley Myles-DiMauro,
Samuel Broderick,
Andrzej S. Kosinski,
Neal S. Kleiman,
Vladimír Džavík,
Jean François Tanguay,
Harish Chandna,
Roger Gammon,
Ernesto Rivera,
John H. Alexander,
Ian Fier,
James Roach,
Richard C. Becker
Publication year - 2010
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.109.913277
Subject(s) - medicine , percutaneous coronary intervention , heparin , myocardial infarction , protamine sulfate , clinical endpoint , randomized controlled trial , low molecular weight heparin , cardiology , anesthesia , surgery , protamine
Factor Xa and factor IIa (thrombin) play roles in thrombotic complications after percutaneous coronary intervention. M118 is a novel low-molecular-weight heparin that has been rationally designed to capture the desired attributes of unfractionated heparin (UFH) and low-molecular-weight heparin: Potent activity against factor Xa and IIa, predictable pharmacokinetics after both intravenous and subcutaneous administration, ability to be monitored by use of point-of-care coagulation assays, and reversibility with protamine sulfate. We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom